Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2026

WARSAW, Ind., Feb. 23, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2026.

PRNewsWire • Feb 23, 2026

ZBH Investor Alert: Hagens Berman Investigates Zimmer Biomet (ZBH) Over Alleged Emerging Market Failures and "Inconsistent" Execution

Partner Reed Kathrein Scrutinizing ZBH's "High Confidence" Assurances After 15% Stock Collapse and Reduced Revenue Guidance SAN FRANCISCO, Feb. 18, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is investigating Zimmer Biomet Holdings, Inc. (NYSE: ZBH) following a series of disclosures that calls into question the reasonable basis for the company's previously expressed "high confidence" in its 2025 revenue targets. The firm urges investors who suffered significant losses to submit your ZBH losses now.

PRNewsWire • Feb 18, 2026

Biggest S&P 500 Winners Last 5, 10, 20 Years

The S&P 500's annualized total return over the last five years has been roughly 13.5%, but the average stock currently in the index has seen an annualized total return about 2.6 percentage points less at just 10.9%.

Seeking Alpha • Feb 19, 2026

A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH

More than just a financial check-up, earnings for companies in the healthcare sector offer a key window for investors into a firm's pipeline and development progress. Even well-established, stable firms in the healthcare space can surprise with growth upon the release of a new blockbuster drug or medical device, and earnings periods are an opportunity for management to provide insight and commentary beyond what investors might expect from FDA notices of approvals, for example.

MarketBeat • Feb 12, 2026

Zimmer Biomet beats quarterly estimates on strong hips, knees device demand

Zimmer Biomet on Tuesday beat Wall Street estimates for fourth-quarter profit and revenue as the company capitalized on steady demand for its devices used in orthopedic procedures.

Reuters • Feb 10, 2026

Zimmer Biomet Holdings, Inc. (ZBH) Q4 2025 Earnings Call Transcript

Zimmer Biomet Holdings, Inc. (ZBH) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 10, 2026

Zimmer Biomet Announces Fourth Quarter and Full-Year 2025 Financial Results

Fourth quarter net sales of $2.244 billion increased 10.9% on a reported basis, 9.2% on a constant currency1 basis and 5.4% on an organic constant currency1 basis Fourth quarter diluted earnings per share were $0.70, a decrease of 41.7%; adjusted1 diluted earnings per share were $2.42, an increase of 4.8% Full-year net sales of $8.232 billion increased 7.2% on a reported basis, 6.4% on a constant currency1 basis and 3.9% on an organic constant currency1 basis Full-year diluted earnings per share were $3.55, a decrease of 19.9%; adjusted1 diluted earnings per share were $8.20, an increase of 2.5% Company provides full-year 2026 financial guidance WARSAW, Ind., Feb. 10, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2025.

PRNewsWire • Feb 10, 2026

Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates

Zimmer Biomet (ZBH) came out with quarterly earnings of $2.42 per share, beating the Zacks Consensus Estimate of $2.38 per share. This compares to earnings of $2.31 per share a year ago.

Zacks Investment Research • Feb 10, 2026

Zimmer (ZBH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Zimmer (ZBH) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Feb 10, 2026

ZBH Q4 Earnings & Revenues Top Estimates, Stock Up in Pre-Market

Zimmer Biomet beats Q4 earnings and revenue estimates, with sales up 10.9% and shares rising 1.4% pre-market despite margin contraction.

Zacks Investment Research • Feb 10, 2026